Short-and long-term pulmonary outcome of palivizumab in children born extremely prematurely

Chest

Volumn 149, Issue 3, 2016, Pages 801-808

  Prais, Dario ^a,b   Kaplan, Eytan ^a,b   Klinger, Gil ^a,b   Mussaffi, Huda ^a,b   Mei Zahav, Meir ^a,b   Bar Yishay, Ephraim ^a,c   Stafler, Patrick ^a,b   Steuer, Guy ^a   Sirota, Lea ^a,b   Blau, Hannah ^a,b  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Bronchopulmonary dysplasia; Pulmonary function test; Respiratory syncytial virus

Indexed keywords

NITRIC OXIDE; PALIVIZUMAB; ANTIVIRUS AGENT;

ARTICLE; ARTIFICIAL VENTILATION; BIRTH WEIGHT; CHILD; CHILDREN BORN EXTREMELY PREMATURELY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; GESTATIONAL AGE; HUMAN; IMMUNOPROPHYLAXIS; LONG TERM OUTCOME; LUNG DIFFUSION; LUNG DYSPLASIA; LUNG FUNCTION; LUNG VOLUME; MALE; MORBIDITY; OUTCOME ASSESSMENT; OXYGEN THERAPY; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK REDUCTION; SCHOOL CHILD; SHORT TERM OUTCOME; SPIROMETRY; WHEEZING; BRONCHOPULMONARY DYSPLASIA; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CROSS-SECTIONAL STUDY; HOSPITALIZATION; LENGTH OF STAY; LONGITUDINAL STUDY; LUNG DIFFUSION CAPACITY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT DISEASES; RESPIRATORY TRACT INFECTIONS; SEASON; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

ANTIVIRAL AGENTS; BRONCHOPULMONARY DYSPLASIA; CASE-CONTROL STUDIES; CHEMOPREVENTION; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HOSPITALIZATION; HUMANS; INFANT, EXTREMELY PREMATURE; LENGTH OF STAY; LONGITUDINAL STUDIES; MALE; PALIVIZUMAB; PROSPECTIVE STUDIES; PULMONARY DIFFUSING CAPACITY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT DISEASES; RESPIRATORY TRACT INFECTIONS; SEASONS; SEVERITY OF ILLNESS INDEX; SPIROMETRY;

EID: 84960333462     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-0328     Document Type: Article

References (28)

1. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588-598.
2. Narang I, Baraldi E, Silverman M, Bush A. Airway function measurements and the long-term follow-up of survivors of preterm birth with and without chronic lung disease. Pediatr Pulmonol. 2006;41(6):497-508.
3. Brooks AM, Byrd RS, Weitzman M, Auinger P, McBride JT. Impact of low birth weight on early childhood asthma in the United States. Arch Pediatr Adolesc Med. 2001;155(3):401-406.
4. Kaplan E, Bar-Yishay E, Prais D, et al. Encouraging pulmonary outcome for surviving, neurologically intact, extremely premature infants in the postsurfactant era. Chest. 2012;142(3):725-733.
5. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354(9178):541-545.
6. Cassimos DC, Tsalkidis A, Tripsianis GA, et al. Asthma, lung function and sensitization in school children with a history of bronchiolitis. Pediatr Int. 2008;50(1):51-56.
7. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005;171(2):137-141.
8. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531-537.
9. Simoes EA, Groothuis JR, Carbonell-Estrany X, et al; Palivizumab Long-Term Respiratory Outcomes Study Group. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007;151(1):34-42.
10. Blanken MO, Rovers MM, Molenaar JM, et al; Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791-1799.
11. Yoshihara S, Kusuda S, Mochizuki H, Okada K, Nishima S, Simões EA; C-CREW Investigators. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics. 2013;132(5):811-818.
12. Simões EA, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick L, Groothuis JR; Palivizumab Long-Term Respiratory Outcomes Study Group. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol. 2010;126(2):256-262.
13. Calişkan M, Bochkov YA, Kreiner-Møller E, et al. Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. N Engl J Med. 2013;368(15): 1398-1407.
14. Wenzel SE, Gibbs RL, Lehr MV, Simoes EA. Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immune globulin. Am J Med. 2002;112(8):627-633.
15. Ehrenkranz RA, Walsh MC, Vohr BR, et al; National Institutes of Child Health and Human Development Neonatal Research Network. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics. 2005;116(6):1353-1360.
16. Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med. 2007;357(19):1946-1955.
17. Miller MR, Crapo R, Hankinson J, et al; ATS/ERS Task Force. General considerations for lung function testing. Eur Respir J. 2005;26(1):153-161.
18. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3): 511-522.
19. Polgar G, Varuni P. Pulmonary Function Testing in Children: Techniques and Standards. Philadelphia, PA: Saunders; 1971:273.
20. Weng TR, Levison H. Standards of pulmonary function in children. Am Rev Respir Dis. 1969;99(6):879-894.
21. Izbicki G, Bar-Yishay E. Methacholine inhalation challenge: a shorter, cheaper and safe approach. Eur Respir J. 2001;17(1):46-51.
22. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000;161(1):309-329.
23. American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171(8): 912-930.
24. Dixon WJ, ed. BMDP statistical software. Los Angeles, CA: University of California; 1993.
25. Jafri HS, Chavez-Bueno S, Mejias A, et al. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J Infect Dis. 2004;189(10): 1856-1865.
26. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99(1):93-99.
27. Lambert RK, Paré PD. Lung parenchymal shear modulus, airway wall remodeling, and bronchial hyperresponsiveness. J Appl Physiol (1985). 1997;83(1): 140-147.
28. Brusasco V, Pellegrino R. Complexity of factors modulating airway narrowing in vivo: relevance to assessment of airway hyperresponsiveness. J Appl Physiol (1985). 2003;95(3):1305-1313.